All the news Showing 10 of 178 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance Bloomberg / 07 August 2017 Reining in Drug Prices: Easier Said than Done MedPage Today / 02 August 2017 Hepatitis C patients unable to get drugs due to funding problems Irish Times / 31 July 2017 Costs for generic hepatitis C drugs available in India would be paid back in 5 to 10 years Massachusetts General Hospital press release / 23 May 2017 France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment Intellectual Property Watch / 03 April 2017 Pharma could take NHS England to court over new delaying tactics PharmaPhorum / 27 March 2017 Industry links with patient organisations BMJ / 27 March 2017 Regulator defends hepatitis charity criticised on BBC show Third Sector / 02 March 2017 Hepatitis C patients 'go abroad for drugs' BBC Radio 4 (audio) / 19 December 2016 Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months ABC Online / 05 December 2016 ← Prev12345...18Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive